Sterility Testing

Overview

Sterility testing demonstrates the absence of viable microorganisms in a product intended for injection, infusion, or implantation. For peptide therapeutics, it is a release test required before human or animal use. Paired with endotoxin testing, sterility assurance protects patients from infection and contamination-driven immune reactions.

USP <71>, EP 2.6.1, and JP 4.06 describe the compendial methods. Compounding pharmacies and research labs should follow their applicable guidance even when preparing small batches.

Regulatory Framework

• USP <71> — direct inoculation and membrane filtration methods
• USP <797> — pharmacy compounding standards, including sterility monitoring for CSPs (compounded sterile preparations)
• 21 CFR 610.12 — FDA biologics sterility testing
• EMA Annex 1 — European GMP for sterile product manufacture

High-risk compounded products require sterility testing before use or well-documented process validation.

Test Methods

Membrane filtration (preferred)

1. Pass sample through a 0.45 μm or 0.22 μm membrane filter
2. Rinse filter with sterile buffer to remove residual peptide, preservatives, and antimicrobials
3. Transfer filter (or halves of it) to fluid thioglycolate medium (FTM) and soybean casein digest medium (SCDM)
4. Incubate FTM at 30–35°C (anaerobes/aerobes) and SCDM at 20–25°C (fungi/aerobes) for 14 days
5. Observe daily for turbidity indicating microbial growth
6. Positive control: spiked organisms demonstrate growth
7. Negative control: medium only, must remain sterile

Direct inoculation

Used when the sample volume is too small or composition interferes with filtration:

• Aliquot sample directly into FTM and SCDM
• Same incubation conditions and duration
• Less sensitive to low-level contamination

Rapid microbial methods (RMM)

Alternative methods acceptable when validated as equivalent:

• ATP bioluminescence — detects living cells quickly (hours)
• Solid-phase cytometry (ScanRDI) — counts cells labeled with viability dye
• Auto-fluorescent particle detection (Bactiflow, MilliFlex)
• PCR-based methods — detect nucleic acids from viable cells

RMMs compress testing from 14 days to hours or days, allowing faster release.

Sample Preparation

• Collect representative samples per USP <71> sample size tables (typically 2% of containers with minimum 20)
• Mix or composite samples per the specific protocol
• Include volume sufficient for both media
• Transfer samples aseptically under a Class 100 (ISO 5) laminar flow hood
• Maintain sterile technique throughout

Handling Antimicrobial Products

Many peptide formulations contain antimicrobial peptides or antifungals (e.g., bacteriostatic water contains benzyl alcohol). These can inhibit growth of any contaminants and mask contamination:

• Rinse and filtration — wash retained contaminants before transfer to media
• Neutralizers — add lecithin, polysorbate, histidine, or specific antibiotic-inactivating enzymes to the media
• Dilution — reduce inhibitory components below effective concentration
• Validation of neutralization — spike challenge organisms and confirm recovery

Suitability testing (method validation) must demonstrate that contaminants, if present, can be recovered from the matrix.

Incubation and Observation

• Observe daily for turbidity, precipitate, color change, or sediment
• Subculture suspicious broths for organism identification
• Record results for full 14-day period — some organisms grow slowly
• If no growth appears, the product passes sterility

Handling positive results

A positive result does not automatically fail the lot. Investigation required:

1. Identify the organism (16S rDNA sequencing, MALDI-TOF)
2. Compare to environmental isolates from the testing facility
3. Review aseptic handling during the test itself
4. Consider retest per USP <71> provisions if the result is attributed to the testing process rather than the product
5. Consult applicable GMP investigation procedures

Document all decisions thoroughly.

Environmental Monitoring

Sterility test areas require ongoing monitoring:

• Settle plates, active air sampling
• Contact plates on surfaces
• Personnel monitoring (gloved hand, gown)
• Trend analysis to detect drift

Frequent environmental isolates often turn up as sterility test positives, informing root cause analysis.

Peptide-Specific Considerations

Filtration compatibility

Some peptides bind to cellulose or PVDF filters. Verify using small test volume and check recovery by HPLC. Switch to low-binding filters if recovery is poor.

Stability of media in presence of peptide

High concentrations of some peptides change media pH or osmolarity, inhibiting microbial growth nonspecifically. Adjust dilution or buffer.

Aggregated peptide

Visible aggregates may mimic microbial growth (precipitates, turbidity). Inspect carefully and distinguish from real growth through microscopy or subculture. See peptide aggregation for relevant background.

Preservatives

Bacteriostatic water and multi-use vials contain benzyl alcohol, which suppresses growth. Account for this in method validation.

Compounding Pharmacy Sterility

Research and clinical peptide compounding often relies on:

• Process validation with media fills (simulate production using sterile growth medium)
• Ongoing sterility testing of representative batches
• BUD (beyond-use date) assignment based on USP <797> category

Small-batch sterility assurance rests heavily on technique and environment more than on batch-by-batch testing.

Documentation

Record:

• Method used, validation reference
• Media lot numbers and expiration dates
• Sample identity and volumes
• Incubation times and temperatures
• Daily observation log
• Positive and negative control outcomes
• Final disposition
• Operator and reviewer signatures

Complementary Tests

Sterility does not ensure safety on its own. Pair with:

• Endotoxin testing — LPS from dead bacteria still pyrogenic
• Quality assessment — chemical purity, potency, visual inspection
• Functional assay — confirms peptide activity intact after processing

Summary

Sterility testing is a rigorous, 14-day confirmation that a peptide product harbors no viable microorganisms. Coupled with endotoxin testing, appropriate aseptic technique during manufacture, and validated rapid methods where applicable, it forms the microbial cornerstone of peptide quality control.